Active Biotech raises SEK 270 million through a directed new issue to Investor

Active Biotech raises SEK 270 million through a directed new issue to Investor 
LUND, SWEDEN -- (Marketwire) -- 03/06/13 --  Active Biotech (NASDAQ
OMX NORDIC: ACTI) today announces that the company's Board of
Directors has, based on the 2012 annual
general meeting's
authorization, resolved to issue in total 6,000,000 new shares
in
Active Biotech to Investor AB (publ). 
The shares are issued at a subscription price of SEK 45 per share,
providing the company with in total approximately SEK 270 million
after transaction costs. The closing price for the Active Biotech
share on NASDAQ OMX Stockholm on March 5, 2013 was SEK 48.80. 
The issue proceeds are intended to be used to strengthen Active
Biotech's capital base and to enable the continued development and
value-growth of the
project portfolio, of which TASQ is financed
under the partner agreement with
Ipsen Pharma, whilst 57-57, ANYARA
and ISI are managed and financed on a proprietary basis. The
development of laquinimod and RhuDex are managed and financed by
partners. The new issue also strengthens Active Biotech's position
in
discussions with potential partners. 
The Board considers it being beneficial for the company and the
shareholders to broaden the shareholder base and to take advantage of
the opportunity to raise
capital on favourable terms for the company
from a strong and well renowned investor. The Board believes that the
new issue, which in light of the above is made with deviation from
the shareholders' pre-emptive rights, will promote the
creation of
value for all shareholders of the company. Active Biotech's two
largest shareholders MGA Holding AB and Nordstjernan AB, and East Bay
AB, with a joint holding of votes and shares of approximately 44
percent, have stated that
they support the new issue. 
Tomas Leanderson, CEO of Active Biotech comments: "I am very pleased
to see that
Active Biotech's project portfolio has obtained
additional financing from Investor. Active Biotech's portfolio has
now matured and, accordingly, our focus
over the next 18-month period
will be on finding suitable partners and partnering structures for
each project. A strong financial position is a prerequisite in order
to succeed with this activity in an optimal way." 
Through the new issue, the number of shares in Active Biotech will
increase by
6,000,000 from 68,923,582 to 74,923,582 and the share
capital will increase by
SEK 22,616,055.93 from SEK 259,796,597.53 to
SEK 282,412,653.46. Investor's holding will correspond to
approximately 8 percent of the shares and votes in
Active Biotech. 
Lund, March 6, 2013 
Active Biotech AB (publ) 
Active  Biotech AB  (NASDAQ OMX  NORDIC: ACTI)  is a  biotechnology
company with
focus  on autoimmune/inflammatory diseases and cancer.
Projects in pivotal phase
are   laquinimod,   an   orally  
administered   small   molecule   with unique
immunomodulatory 
properties for the  treatment of multiple  sclerosis, TASQ for
prostate  cancer and ANYARA primarily for the treatment of renal cell
cancer. In addition,  laquinimod  is  in  Phase  II  development for
Crohn's and Lupus. The company  also has  one additional  project in 
clinical development,  the orally
administered    compound    57-57
for    Systemic    Sclerosis.   Please visit
www.activebiotech.com
for more information. 
Active Biotech is obligated to publish the information contained in
this press
release in accordance with the Swedish Securities Market
Act. This information
was provided to the media for publication 8:30
a.m. CET on March 6, 2013. 
Active Biotech raises SEK 270 million through a directed new issue to
: 
http://hugin.info/1002/R/1683237/550842.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Active Biotech via Thomson Reuters ONE 
[HUG#1683237] 
For further information, please contact:
Tomas Leanderson
CEO
Tel: +46 (0)46 19 20 95
E-mail: tomas.leanderson@activebiotech.com 
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
E-mail: hans.kolam@activebiotech.com 
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
 
 
Press spacebar to pause and continue. Press esc to stop.